Erosive Lichen Planus

Comprehensive Clinical Guide: Erosive Lichen Planus (ELP)

Erosive Lichen Planus (ELP) represents the most severe, painful, and clinically challenging phenotypic variant of oral lichen planus (OLP). While classic reticular OLP is often asymptomatic, the erosive/ulcerative form is characterized by persistent, painful mucosal erosions that significantly impair a patient’s quality of life, nutritional intake, and overall oral health. As a chronic, T-cell-mediated autoimmune condition, ELP requires a sophisticated, multidisciplinary approach to management, balancing immunosuppression with long-term surveillance for malignant transformation.

1. Clinical Definition and Overview

Erosive Lichen Planus is a chronic inflammatory autoimmune disorder primarily affecting the stratified squamous epithelium of the oral mucosa. It is categorized under the umbrella of Lichen Planus but is distinguished by the presence of atrophic, erythematous, and ulcerated areas bordered by radiating white striae (Wickham striae).

Unlike the quiescent reticular form, ELP is clinically defined by its fragility. The epithelium is thin and prone to spontaneous bleeding and secondary infection. It is a persistent condition that typically follows a relapsing-remitting course, often requiring systemic intervention rather than simple topical management.

2. Etiology and Pathophysiology

The exact etiology of ELP remains multifactorial, involving a complex interplay between genetic predisposition, environmental triggers, and immune dysregulation.

The Mechanism of Autoimmunity

At the core of ELP pathophysiology is a cell-mediated immune response directed against basal keratinocytes.
* Antigen Presentation: It is hypothesized that an unknown antigen—possibly a self-antigen or a modified protein—is presented to CD8+ cytotoxic T-lymphocytes.
* T-Cell Recruitment: Activated T-cells infiltrate the lamina propria and migrate into the epithelium, releasing cytokines such as Interferon-gamma (IFN-γ) and Tumor Necrosis Factor-alpha (TNF-α).
* Keratinocyte Apoptosis: The release of Granzyme B and Perforin by CD8+ T-cells triggers apoptosis in the basal cell layer.
* Basement Membrane Breakdown: In ELP, the destruction of the basal layer is so profound that the epithelium detaches from the underlying connective tissue, resulting in the characteristic "erosive" or "ulcerative" clinical presentation.

Key Triggering Factors

3. Clinical Presentation and Staging

Standard Clinical Presentation

Patients with ELP typically present with severe pain, often described as a burning sensation. Triggers include acidic foods, spices, and even routine oral hygiene.
* Appearance: Central red (erythematous) zone surrounded by a halo of white, reticular striae.
* Distribution: Bilateral buccal mucosa is the most common site, though it can involve the tongue (often leading to atrophy of filiform papillae), gingiva (desquamative gingivitis), and the palate.
* Gingival Involvement: "Desquamative gingivitis" is a hallmark sign where the gingiva appears bright red, raw, and bleeds easily upon contact.

Clinical Staging (REU Score)

The Reticulation, Erythema, and Ulceration (REU) scoring system is the standard for quantifying the severity of ELP:
1. Reticulation: Scoring the presence of white striae.
2. Erythema: Scoring the area of redness.
3. Ulceration: Scoring the area of frank mucosal break.

4. Differential Diagnosis

Distinguishing ELP from other vesiculobullous diseases is critical, as treatment protocols differ significantly.

• Pemphigus Vulgaris: Characterized by suprabasal acantholysis; usually involves positive Nikolsky sign.
• Mucous Membrane Pemphigoid (MMP): Subepithelial blistering; often involves ocular or genital mucosa (cicatricial scarring).
• Chronic Ulcerative Stomatitis (CUS): Clinically identical to ELP but shows specific anti-nuclear antibodies (anti-stratified epithelium).
• Erythema Multiforme: Acute onset, often targetoid lesions, history of herpes simplex or drug reaction.
• Lichenoid Drug Reaction: Must be ruled out by reviewing the patient’s medication history.

5. Diagnostic Testing

A definitive diagnosis of ELP requires a combination of clinical assessment and histopathology.

Histopathologic Features

• Hyperkeratosis/Parakeratosis: Thickening of the stratum corneum.
• Saw-tooth Rete Ridges: A classic architectural finding.
• Basal Cell Liquefaction: Destruction of the basal layer.
• Band-like Lymphocytic Infiltrate: A dense collection of T-cells at the dermo-epidermal junction.
• Civatte Bodies: Degenerating keratinocytes found in the basement membrane zone.

Immunofluorescence

• Direct Immunofluorescence (DIF): Essential to rule out Pemphigoid or Pemphigus. In ELP, DIF often shows shaggy fibrinogen deposition along the basement membrane zone.

6. Management and Therapeutic Strategy

The primary goals are pain control, reduction of inflammation, and prevention of secondary infection.

First-Line Therapy

• High-Potency Topical Corticosteroids: Clobetasol propionate 0.05% in an adhesive base (Orabase) is the gold standard.
• Calcineurin Inhibitors: Tacrolimus 0.1% ointment or Pimecrolimus. These are effective but carry a theoretical risk of long-term malignancy and should be used with caution.

Systemic Therapy (For Refractory Cases)

• Systemic Corticosteroids: Prednisone (short-term bursts for acute flares).
• Immunomodulators: Mycophenolate mofetil, Azathioprine, or Hydroxychloroquine.
• Biologics: Emerging data on anti-TNF agents (e.g., adalimumab) for recalcitrant cases.

7. Risks and Contraindications

Malignant Transformation

ELP is considered a Potentially Malignant Disorder (PMD). The risk of transformation into Squamous Cell Carcinoma (SCC) is estimated between 1% and 3%.
* Risk Factors for Transformation: Long-standing disease, tobacco use, alcohol consumption, and persistent HPV co-infection.
* Surveillance: Patients must undergo clinical examination every 3–6 months. Any lesion that does not resolve with standard therapy requires an immediate biopsy.

Contraindications

• Avoidance of Irritants: Patients must avoid alcohol-based mouthwashes, SLS (Sodium Lauryl Sulfate) toothpastes, and spicy foods during active flares.
• Steroid Overuse: Long-term topical steroids can lead to secondary candidiasis. Prophylactic antifungal therapy (e.g., Nystatin or Fluconazole) is often required.

8. Frequently Asked Questions (FAQ)

1. Is Erosive Lichen Planus contagious?

No. ELP is an autoimmune condition, not an infection. It cannot be transmitted through kissing, sharing utensils, or any other form of contact.

2. Can ELP be cured completely?

Currently, there is no permanent "cure." It is a chronic condition that can be managed effectively to achieve long periods of remission.

3. Why is my gingiva so red and painful?

This is known as desquamative gingivitis. The immune system is attacking the surface layer of the gums, leaving the underlying tissue exposed and raw.

4. Is there a link between ELP and cancer?

Yes. ELP is classified as a potentially malignant disorder. Regular monitoring is essential to detect early signs of squamous cell carcinoma.

5. Does diet affect my ELP?

Yes. Acidic (citrus, tomatoes), spicy, and crunchy foods can exacerbate pain and irritation. A bland, non-irritating diet is recommended during flare-ups.

6. Are there specific medications that trigger ELP?

Yes. Certain medications like NSAIDs, beta-blockers, and anti-hypertensives can cause "lichenoid" reactions that mimic ELP. Always review your medication list with your doctor.

7. How often should I have a biopsy?

If you have a confirmed diagnosis, you don't need a biopsy every visit. However, if a specific area of the lesion changes in texture, thickness, or fails to respond to treatment, a repeat biopsy is mandatory.

8. Can stress cause a flare-up?

Absolutely. Stress is one of the most common triggers for ELP exacerbations. Stress management techniques are an integral part of the treatment plan.

9. What is the role of oral hygiene in ELP?

Paradoxically, poor oral hygiene can worsen ELP by increasing the bacterial load. Patients should use a soft-bristled toothbrush and a non-irritating, SLS-free toothpaste.

10. Can ELP affect other parts of the body?

Yes. While oral involvement is most common, ELP can also affect the genital mucosa, esophagus, and skin.

9. Conclusion and Long-Term Prognosis

The prognosis for patients with Erosive Lichen Planus is generally favorable regarding systemic health, provided the patient adheres to a strict follow-up schedule. While the disease is chronic and frequently uncomfortable, modern topical and systemic immunomodulatory therapies allow most patients to lead normal lives.

The primary clinical responsibility of the practitioner is twofold:
1. Symptom Management: Implementing aggressive topical steroid protocols to improve the patient’s quality of life.
2. Vigilance: Maintaining a low threshold for biopsy to ensure that any potential malignant transformation is intercepted at the earliest possible stage.

Patients should be empowered with education regarding their condition, emphasizing that while ELP is a lifelong companion, it is a manageable one. Coordination between oral medicine specialists, dermatologists, and primary care physicians remains the gold standard for comprehensive patient care.